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Abstract
© 2016  Springer  Science+Business  Media  New YorkCurrent  treatment  options  of  chronic,
progressive degenerative neuropsychiatric conditions offer only marginal efficacy, and there is
no therapy which arrests or even reverses these diseases. Interest in genetic engineering and
cell-based approaches have constantly been increasing, although most of them so far proved to
be fruitless or at best provided very slight clinical benefit. In the light of the highly complex
patho-mechanisms of these maladies, the failure of drugs aimed at targeting single molecules is
not surprising. In order to improve their effectiveness, the role of a unique triple-combination
gene therapy was investigated in this study. Intravenous injection of human umbilical cord blood
mononuclear  cell  (hUCBMC)  cotransduced  with  adenoviral  vectors  expressing  vascular
endothelial growth factor (VEGF), glial cell-derived neurotrophic factor (GDNF), and neural cell
adhesion molecule (NCAM) resulted in prominent increase of  life span and performance in
behavioral tests in amyotrophic lateral sclerosis (ALS). Expression of the recombinant genes in
hUCBMCs was confirmed as soon as 5 days after  transduction by RT-PCR,  and cells  were
detectable for as long as 1 month after grafting in lumbar spinal cord by immunofluorescent
staining.  Xenotransplantation  of  cells  into  mice  blood  without  any  immunosuppression
demonstrated a high level of hUCBMCs homing and survivability in the central nervous system
(CNS), most conspicuously in the spinal cord, but not in the spleen or liver. This study confirms
an increased addressed homing and notable survivability of triple-transfected cells in lumbar
spinal cord, yielding a remarkably enhanced therapeutic potential of hUCBMCs overexpressing
neurotrophic factors.
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